Suppr超能文献

经导管与心外膜导线放置在心脏再同步治疗中的比较。

Comparison of endovascular versus epicardial lead placement for resynchronization therapy.

机构信息

Division of Cardiology, Wright State University Boonshoft School of Medicine, Dayton, Ohio.

The Arrhythmia Institute, Valley Health System, Ridgewood, New Jersey; Columbia University College of Physicians and Surgeons, New York, New York.

出版信息

Am J Cardiol. 2014 Mar 1;113(5):840-4. doi: 10.1016/j.amjcard.2013.11.040. Epub 2013 Dec 12.

Abstract

Cardiac resynchronization therapy (CRT) has been shown to improve survival and symptoms in patients with severe left ventricular (LV) dysfunction, congestive heart failure, and prolonged QRS duration. LV lead placement is achieved by placing the lead in the coronary sinus, an endovascular approach, or by a minimally invasive robotic-assisted thoracoscopic epicardial approach. There are no data directly comparing the 2 methods. Patients eligible for CRT were randomized to the endovascular and epicardial arms. Coronary sinus lead placement was achieved using the standard technique, and epicardial leads were placed using a minimally invasive robotic-assisted thoracoscopic approach. The primary end point was a decrease in LV end-systolic volume index at 6 months. The secondary end points included 30-day mortality rate, measures of clinical improvement, 1-year electrical lead performance, and 1-year survival rate. The relative improvement of LV end-systolic volume index from baseline to 6 months was similar between the arms (28.8% for the transvenous [n = 12] vs 30.5% for the epicardial (n = 9) arm, p = 0.93). There were no significant differences in the secondary end points between the 2 groups. In conclusion, there were no differences in echocardiographic and clinical outcomes comparing a conventional endovascular approach versus robotic-assisted surgical epicardial LV lead placement for CRT in patients with heart failure. Surgical approaches are still a viable alternative when a transvenous procedure has failed or is not technically feasible.

摘要

心脏再同步治疗(CRT)已被证明可改善严重左心室(LV)功能障碍、充血性心力衰竭和 QRS 持续时间延长患者的生存率和症状。LV 导联的放置是通过将导联放置在冠状窦(一种血管内方法)或通过微创机器人辅助胸腔镜心外膜方法来实现的。目前尚无直接比较这两种方法的数据。符合 CRT 条件的患者被随机分配到血管内和心外膜臂。使用标准技术实现冠状窦导联放置,使用微创机器人辅助胸腔镜方法放置心外膜导联。主要终点是 6 个月时 LV 收缩末期容积指数的降低。次要终点包括 30 天死亡率、临床改善措施、1 年电导联性能和 1 年生存率。从基线到 6 个月时,LV 收缩末期容积指数的相对改善在两个臂之间相似(经静脉[n = 12]为 28.8%,心外膜[n = 9]为 30.5%,p = 0.93)。两组在次要终点之间无显著差异。总之,对于心力衰竭患者,与常规血管内方法相比,使用机器人辅助手术心外膜 LV 导联放置 CRT 在超声心动图和临床结局方面没有差异。当经静脉程序失败或技术上不可行时,手术方法仍然是一种可行的替代方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验